Now that the European Union's schem...

Now that the European Union's scheme for promoting orphan medicines is up and running fortunately the EU is turning its attention to the treatment of diseases in children. And its plan to boost the industry's attention to developing pediatric treatments owes abundant to the incentive schemes the EU has used for orphans--and a great quantity [i]or[/i] amount of more to the late U.S. thinking, too.
The EU freshly set out its thinking in a consultation document, (1) which emphasizes the ne for action--given that up to 90% of medicines administered to children have not at all been specifically tested for use in